Theriva Biologics' Q2 Net Loss Widens to $10.5M Amid Clinical Trials

TL;DR

**TOVX is burning cash with no revenue, making it a risky bet until VCN-01 shows significant clinical progress.**

AI Summary

Theriva Biologics, Inc. (TOVX) reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage biotechnology status. The company experienced a net loss of $10.5 million for the three months ended June 30, 2025, compared to a net loss of $9.8 million for the same period in 2024, representing a 7.1% increase in net loss. For the six months ended June 30, 2025, the net loss was $20.1 million, an increase from $19.0 million in the prior year, reflecting a 5.8% rise. Key business changes include ongoing clinical trials for its lead product candidates, particularly VCN-01, which is in a Phase 2 clinical trial for pancreatic cancer. The company's strategic outlook focuses on advancing its oncology pipeline and securing additional financing to support these efforts. Risks include the significant capital requirements for drug development and the uncertainty of clinical trial success, as evidenced by the accumulated deficit of $405.7 million as of June 30, 2025.

Why It Matters

Theriva Biologics' widening net loss to $10.5 million in Q2 2025 underscores the significant capital burn inherent in clinical-stage biotech, directly impacting investor confidence and future financing rounds. For employees, continued losses could signal potential restructuring or a slower pace of hiring. Customers, primarily future patients, are reliant on the successful and timely progression of VCN-01 through trials. In a competitive oncology market, Theriva's ability to secure funding and achieve positive clinical milestones is crucial for its long-term viability and market positioning against larger pharmaceutical companies with deeper pockets.

Risk Assessment

Risk Level: high — The risk level is high due to Theriva Biologics reporting no revenue for the three and six months ended June 30, 2025, and an accumulated deficit of $405.7 million as of June 30, 2025. This indicates a complete reliance on external financing and a substantial history of losses, posing significant going concern risks.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor closely for significant clinical trial data for VCN-01 and any new financing announcements, as these are critical for the company's survival.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10.5M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for Q2 2025, indicating a clinical-stage company.)
• $10.5M — Net Loss (Q2 2025) (Increased from $9.8M in Q2 2024, showing widening losses.)
• $20.1M — Net Loss (YTD Q2 2025) (Increased from $19.0M in YTD Q2 2024, reflecting continued operational expenses.)
• $405.7M — Accumulated Deficit (As of June 30, 2025, highlighting significant historical losses.)
• 7.1% — Increase in Q2 Net Loss (Percentage increase in net loss from Q2 2024 to Q2 2025.)
• 5.8% — Increase in YTD Net Loss (Percentage increase in net loss from YTD Q2 2024 to YTD Q2 2025.)

Key Players & Entities

• Theriva Biologics, Inc. (company) — filer of the 10-Q
• VCN-01 (product) — lead product candidate in Phase 2 clinical trial for pancreatic cancer
• $10.5 million (dollar_amount) — net loss for the three months ended June 30, 2025
• $9.8 million (dollar_amount) — net loss for the three months ended June 30, 2024
• $20.1 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $19.0 million (dollar_amount) — net loss for the six months ended June 30, 2024
• $405.7 million (dollar_amount) — accumulated deficit as of June 30, 2025
• June 30, 2025 (date) — end of the reporting period for the 10-Q
• Bloomberg (company) — publisher of the analysis
• SEC (regulator) — regulator for 10-Q filings

FAQ

Risk Factors

• Significant Accumulated Deficit [high — financial]: As of June 30, 2025, Theriva Biologics has an accumulated deficit of $405.7 million. This indicates substantial historical losses and a reliance on external funding to sustain operations and development activities.
• Dependence on Future Financing [high — financial]: The company's strategic outlook emphasizes securing additional financing to support its oncology pipeline advancement. Without sufficient capital, Theriva Biologics may be unable to fund its ongoing clinical trials and research and development efforts.
• Clinical Trial Uncertainty [high — operational]: The success of Theriva Biologics is contingent upon the successful outcomes of its clinical trials, particularly for VCN-01 in pancreatic cancer. Clinical trials are inherently risky, with no guarantee of efficacy or safety, which could lead to significant setbacks.
• Increasing Net Losses [medium — financial]: For the three months ended June 30, 2025, the net loss was $10.5 million, a 7.1% increase from $9.8 million in the prior year. The six-month net loss also increased by 5.8% to $20.1 million. This trend indicates rising operational costs without corresponding revenue.
• Regulatory Approval Risk [high — regulatory]: As a biotechnology company, Theriva Biologics is subject to stringent regulatory review processes by bodies like the FDA. Failure to obtain regulatory approval for its product candidates would prevent commercialization and impact future revenue streams.

Industry Context

The biotechnology industry, particularly the oncology segment, is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Companies like Theriva Biologics operate in a competitive landscape where innovation is key, but success is often dependent on securing substantial funding and achieving positive clinical trial outcomes.

Regulatory Implications

Theriva Biologics faces significant regulatory risks inherent in drug development. The company must navigate complex approval processes with agencies like the FDA. Any delays or failures in clinical trials for its candidates, such as VCN-01, could have severe financial and operational consequences.

What Investors Should Do

1. Monitor cash burn rate and future financing activities.
2. Evaluate clinical trial progress and data readouts.
3. Assess the competitive landscape in pancreatic cancer treatment.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing $0 revenue and a net loss of $10.5 million.
• 2025-08-11: 10-Q Filing Date — The company officially submitted its quarterly financial report, providing detailed financial statements and business updates.

Glossary

Clinical-stage biotechnology

A company focused on developing new drugs or therapies that are currently undergoing testing in human clinical trials, rather than selling approved products. (Explains why Theriva Biologics has no revenue and incurs significant research and development expenses.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, less any cumulative net income. It represents the total amount of money a company has lost over its history. (Highlights the significant historical losses of Theriva Biologics, totaling $405.7 million as of June 30, 2025.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Indicates the company's current financial performance, showing an increase in losses for the reported periods.)

VCN-01

Theriva Biologics' lead product candidate, currently in Phase 2 clinical trials for pancreatic cancer. (Represents a key asset and focus of the company's development pipeline.)

Year-Over-Year Comparison

Compared to the previous year's filing, Theriva Biologics continues to report no revenue, consistent with its clinical-stage status. Net losses have widened, with Q2 2025 losses increasing by 7.1% and year-to-date losses by 5.8%, indicating increased operational expenses. The accumulated deficit has also grown, underscoring the ongoing need for capital. No new significant risks were highlighted, but the existing risks related to financing and clinical trial success remain paramount.

Key Financial Figures

• $0.001 — t had 9,597,952 shares of common stock, $0.001 par value per share, outstanding. Tabl

Filing Documents

• tmb-20250630x10q.htm (10-Q) — 1594KB
• tmb-20250630xex31d1.htm (EX-31.1) — 14KB
• tmb-20250630xex32d1.htm (EX-32.1) — 7KB
• tmb-20250630x10q001.jpg (GRAPHIC) — 40KB
• 0001410578-25-001654.txt ( ) — 7037KB
• tmb-20250630.xsd (EX-101.SCH) — 55KB
• tmb-20250630_cal.xml (EX-101.CAL) — 54KB
• tmb-20250630_def.xml (EX-101.DEF) — 178KB
• tmb-20250630_lab.xml (EX-101.LAB) — 455KB
• tmb-20250630_pre.xml (EX-101.PRE) — 327KB
• tmb-20250630x10q_htm.xml (XML) — 1151KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 44 Item 4.

Controls and Procedures

Controls and Procedures 44

OTHER INFORMATION

PART II. OTHER INFORMATION 45 Item 1.

Legal Proceedings

Legal Proceedings 45 Item 1A.

Risk Factors

Risk Factors 45 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 Item 3. Defaults Upon Senior Securities 47 Item 4. Mine Safety Disclosures 47 Item 5. Other Information 47 Item 6. Exhibits 48

SIGNATURES

SIGNATURES 50 2 Table of Contents

–FINANCIAL INFORMATION

PART I–FINANCIAL INFORMATION

FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) Theriva Biologics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands except share and par value amounts) June 30, 2025 December 31, 2024 Assets Current Assets Cash and cash equivalents $ 12,120 $ 11,609 Tax credit receivable 1,722 3,228 Prepaid expenses and other current assets 901 1,444 Total Current Assets 14,743 16,281 Non-Current Assets Property and equipment, net 258 270 Restricted cash 46 96 Right of use asset 1,077 1,272 In-process research and development 19,624 17,358 Deposits and other assets 82 75 Total Assets $ 35,830 $ 35,352 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable $ 607 $ 859 Accrued expenses 9,017 3,368 Accrued employee benefits 759 1,144 Deferred research and development tax credit-current portion 1,343 1,614 Loans payable-current 56 61 Operating lease liability-current portion 612 539 Total Current Liabilities 12,394 7,585 Non-current Liabilities Non-current contingent consideration 10,160 6,973 Loan Payable - non-current 1,639 92 Non-current deferred research and development tax credit 430 762 Non-current operating lease liability 584 873 Total Liabilities 25,207 16,285 Commitments and Contingencies (Note 13) Stockholders' Equity: Preferred Stock; 10,000,000 authorized; none issued or outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 350,000,000 shares authorized, 9,088,042 issued and 9,059,232 outstanding at June 30, 2025 and 2,811,259 issued and 2,782,449 outstanding at December 31, 2024 8 3 Additional paid-in capital 362,463 355,501 Treasury stock at cost, 28,809 shares at June 30, 2025 and at December 31, 2024 ( 288 ) ( 288 ) Accumulated other comprehensive income (loss) 793 ( 1,178 ) Accumulated deficit ( 352,353 ) ( 334,971 ) Total St

View Full Filing

View this 10-Q filing on SEC EDGAR